Tag: ibdoc

Usability of a Home-Based Test for the Measurement of Fecal Calprotectin in Asymptomatic IBD Patients Digestive and Liver Disease

IBDoc® Citation: Bello C, Roseth A, Guardiola J, Reenaers C, Ruiz-Cerulla A, Kemseke C Van, Arajol C, Reinhard C, Seidel L, Louis E.Usability of a home-based test for the measurement of fecal calprotectin in asymptomatic IBD patients. Digestive and Liver Disease. 2017 May 19. pii: S1590-8658(17)30886-1. http://dx.doi.org/10.1016/j.dld.2017.05.009 PMID: 28587751 Highlights from this Publication “ …Globally, the correlation between

New Health Canada Licences: Quantum Blue® Infliximab Assay, IBDoc®,CALEX® Cap

BUHLMANN Diagnostics Corp (BDC), BÜHLMANN Laboratories AG’s North American affiliate is proud to announce that three of its novel products, Quantum Blue® Infliximab Assay, IBDoc® and CALEX®Cap have received Medical Device Licences from Health Canada and are now commercially available in Canada. Quantum Blue® Infliximab® and CALEX® CAP devices were approved as Class 2 medical devices

BÜHLMANN Laboratories AG (BL), based in Basel Switzerland, has been discovering, developing & manufacturing innovative chemistry and immunological in-vitro diagnostic (IVD) and research use only (RUO) assays for almost 50 years (circa 1976). As the United States commercial affiliate of BL, BUHLMANN Diagnostics Corp (BDC), based in Amherst, NH is committed to providing exceptional sales, support, and technical services to our clinical, discovery and basic science research laboratory customers.

Tag: ibdoc

Usability of a Home-Based Test for the Measurement of Fecal Calprotectin in Asymptomatic IBD Patients Digestive and Liver Disease

New Health Canada Licences: Quantum Blue® Infliximab Assay, IBDoc®,CALEX® Cap

ABOUT US

SOCIAL MEDIA

QUICK LINKS

CONTACT US